Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Is there a role for fatty acid synthase in the diagnosis of prostatic adenocarcinoma?: A comparison with AMACR.

Wu X, Zayzafoon M, Zhang X, Hameed O.

Am J Clin Pathol. 2011 Aug;136(2):239-46. doi: 10.1309/AJCP0Y5QWWYDKCJE.

2.

Reliability of the 34βE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma.

Boran C, Kandirali E, Yilmaz F, Serin E, Akyol M.

Urol Oncol. 2011 Nov-Dec;29(6):614-23. doi: 10.1016/j.urolonc.2009.11.013. Epub 2010 Mar 2.

PMID:
20189848
3.

Is there a role for prostate tumour overexpressed-1 in the diagnosis of HGPIN and of prostatic adenocarcinoma? A comparison with alpha-methylacyl CoA racemase.

Scarpelli M, Mazzucchelli R, Barbisan F, Santinelli A, Lopez-Beltran A, Cheng L, Montironi R.

Int J Immunopathol Pharmacol. 2012 Jan-Mar;25(1):67-74.

PMID:
22507319
5.

Alpha methylacyl-CoA racemase (AMACR) in prostate adenocarcinomas from Japanese patients: is AMACR a "race"-dependent marker?

Yamada H, Tsuzuki T, Maeda N, Yamauchi Y, Yoshida S, Ishida R, Nishikimi T, Yokoi K, Kobayashi H.

Prostate. 2013 Jan;73(1):54-9. doi: 10.1002/pros.22539. Epub 2012 May 16.

PMID:
22593005
6.

Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy.

Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, de Marzo AM, Epstein JI.

Am J Surg Pathol. 2003 Aug;27(8):1128-33.

PMID:
12883245
7.

Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.

Schostak M, Miller K, Krause H, Schrader M, Kempkensteffen C, Kollermann J.

Cancer Detect Prev. 2006;30(5):449-54. Epub 2006 Oct 25.

PMID:
17067752
8.
9.

Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S).

Jiang Z, Woda BA, Wu CL, Yang XJ.

Am J Clin Pathol. 2004 Aug;122(2):275-89. Review.

10.

Altered expression of alpha-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy.

Suzue K, Montag AG, Tretiakova M, Yang XJ, Sahoo S.

Am J Clin Pathol. 2005 Apr;123(4):553-61.

12.

Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.

Jiang Z, Wu CL, Woda BA, Iczkowski KA, Chu PG, Tretiakova MS, Young RH, Weiss LM, Blute RD Jr, Brendler CB, Krausz T, Xu JC, Rock KL, Amin MB, Yang XJ.

Histopathology. 2004 Sep;45(3):218-25.

PMID:
15330799
13.

Utility of ERG versus AMACR expression in diagnosis of minimal adenocarcinoma of the prostate in needle biopsy tissue.

Andrews C, Humphrey PA.

Am J Surg Pathol. 2014 Jul;38(7):1007-12. doi: 10.1097/PAS.0000000000000205.

PMID:
24705308
14.

Comparison of the diagnostic value of fatty acid synthase (FASN) with alpha-methylacyl-CoA racemase (AMACR) as prostatic cancer tissue marker.

Tischler V, Fritzsche FR, Gerhardt J, Jäger C, Stephan C, Jung K, Dietel M, Moch H, Kristiansen G.

Histopathology. 2010 May;56(6):811-5. doi: 10.1111/j.1365-2559.2010.03535.x. No abstract available.

PMID:
20546348
15.
16.
17.

Detection of alpha-methylacyl-coenzyme A racemase in postradiation prostatic adenocarcinoma.

Yang XJ, Laven B, Tretiakova M, Blute RD Jr, Woda BA, Steinberg GD, Jiang Z.

Urology. 2003 Aug;62(2):282-6.

PMID:
12893336
18.

Foamy gland carcinoma of the prostate in needle biopsy: incidence, Gleason grade, and comparative α-methylacyl-CoA racemase vs. ERG expression.

Warrick JI, Humphrey PA.

Am J Surg Pathol. 2013 Nov;37(11):1709-14. doi: 10.1097/PAS.0b013e318293d85b.

PMID:
23797726
19.

P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy.

Jiang Z, Wu CL, Woda BA, Dresser K, Xu J, Fanger GR, Yang XJ.

Am J Surg Pathol. 2002 Sep;26(9):1169-74.

PMID:
12218573
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk